272 related articles for article (PubMed ID: 6458280)
1. The separation of functionally distinct forms of the third component of human complement (C3).
Parkes C; DiScipio RG; Kerr MA; Prohaska R
Biochem J; 1981 Mar; 193(3):963-70. PubMed ID: 6458280
[TBL] [Abstract][Full Text] [Related]
2. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
3. Purification of the human complement control protein C3b inactivator.
Crossley LG; Porter RR
Biochem J; 1980 Oct; 191(1):173-82. PubMed ID: 6451220
[TBL] [Abstract][Full Text] [Related]
4. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
Pangburn MK; Müller-Eberhard HJ
J Exp Med; 1980 Oct; 152(4):1102-14. PubMed ID: 6903192
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
6. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
7. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.
Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K
J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382
[TBL] [Abstract][Full Text] [Related]
9. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
10. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
13. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
14. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1977 Jul; 146(1):257-70. PubMed ID: 301546
[TBL] [Abstract][Full Text] [Related]
15. Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b.
Koistinen V
Biochem J; 1991 Nov; 280 ( Pt 1)(Pt 1):255-9. PubMed ID: 1835839
[TBL] [Abstract][Full Text] [Related]
16. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae.
Jimenez-Lucho VE; Joiner KA; Foulds J; Frank MM; Leive L
J Immunol; 1987 Aug; 139(4):1253-9. PubMed ID: 2440949
[TBL] [Abstract][Full Text] [Related]
17. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
DiScipio RG
Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
[TBL] [Abstract][Full Text] [Related]
18. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
19. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
Medicus RG; Melamed J; Arnaout MA
Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
[TBL] [Abstract][Full Text] [Related]
20. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]